price-to-earnings need
wall worri high short interest head earn quit high
question around virtual key segment backdrop deliv
impress perform aid better core result well one-tim
benefit quarter prior-year develop invest portfolio gain
importantli three segment came expect ebit front
end trend better expect pbm script growth acceler concern
cost trend relat strong enrol growth materi
certainli small pocket weak small piec mid-market commerci
cost trend issu move piec gross margin stock trade sub-
ep head quarter achiev perfect what expect buy
rate predic abil enterpris transform/adapt new
total cost manag healthcar conveni model noth saw
quarter chang view reiter buy rate po
price-to-earnings see risk/reward strong cash flow gener quit appeal
current level
increas ep ep
increas ep driven primarili beat includ stronger
ebit growth pharmaci servic retail/long term well slightli lower
interest rate assumpt price object remain unchang repres
ep estim
upcom event catalyst
way focu remaind year updat
pbm sell season/ma enrol well addit commentari near-term
intermedi term initi expans healthhub model
synergi realiz rx growth key event watch includ legislation/regulatori
updat relat drug price broadli particularli part rebat rule
pull last month
net dbt
enough box check drive
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest healthcar compani
unit state provid retail mail
specialti pharmaci dispens servic
pharmaci benefit upon complet
acquisit aetna would becom one
vertic integr publicli trade
healthcar compani base
buy rate driven transform
vertic integr aetna stabl free cash
flow appeal valuat think
compani deal aetna provid ampl short-
term long-term synergi opportun
provid clear way extract valu
retail franchis stabl free cash flow
three busi allow
compani gener outsiz return
equiti next year
ep exceed high-end rang driven stronger expect result
across board
believ compani acceler shift pdp could result
lower growth silverscript
first wave ingeniorx ad platform migrat gone flawlessli
chronic kidney care program last month receiv fda approv begin
clinic trial dialysi plan expect trial finish month launch
expect contribut synergi
increas synergi come formulari benefit
withdraw rebat rule support recognit pbm valu
signific cost impact would result elimin
power formulari drive discount lower premium
benefit quarter due part prior year develop non-
recur benefit also benefit due better tax rate function time
lower expect interest rate
expect mbr /- bia toward upper end
compani obtain synergi ahead expect
synergi contribut quarter
out-performance due formulari optim compani
transit function faster thought one exampl mail
next year remain tact
script growth come clinic program
pbm benefit quarter increas synergi
came key area strong perform overal
prescript growth mail choic mainten choic
higher rebat earn quarter
healthhub trend traffic way put number around stori
next year could healthhub look like compani
need store provid quantit data
store healthhub store updat total store count
dont target store count continu evalu real estat
reduc new store open open year expect
open new store compar new store open
year ago
strategi next year declin silverscript could benefit dual
busi help quantifi opportun
modifi design drive convers silverscript
pbm sell season part market win
done sell season
larg ep beat seem like fy ep beat could rais
impli guidanc anyth call
pleas execut quarter
gener impact rebat guarante
lower profit aetna season
retail seem like front store improv feel comp
trajectori
pleas front store busi
growth come health beauti strategi take share
store remodel impact comp
bid pbm
go market strategi includ offer new supplement benefit
leverag enterpris minuteclin offer zero/low copay
sourc much anyth china
sizabl busi goe outsid domest
impact term current trade issu havent seen anyth
materi busi
continu monitor someth command lot
attent point
perform medicaid
current state
mbr perform line expect
new contract kansa perform compani
thought would
silverscript opportun aetna experi typic
convers rate pdp
excit possibl growth
aetna stand-alone compani convert
skew toward earlier year rang
trend comment medicar medicaid broadli across busi
gener medic cost trend in-lin across board
comment guidanc beat
item capit gain prior year
creat seamless experi exist
chang prior expect
price object base ep estim multipl
five-year averag absolut basi lower end histor
rang also repres bigger discount vs last
retail pharmaci segment uncertainti around drug price
downsid risk po risk amazon anoth disrupt forc enter
suppli chain failur gener gener expect synergi aetna
transact regulatori issu relat post-clos activ grow
competit risk pharmaci benefit market includ competit price around
rebat on-going oper challeng long-term care pharmaci busi
headlin relat opioid litig slow prescription/insur trend upsid
risk po potenti prescript volum pickup faster stronger
expect synergi aetna improv front-end perform
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
